Stokes Capital Advisors LLC Makes New $203,000 Investment in Pfizer Inc. (NYSE:PFE)

Stokes Capital Advisors LLC purchased a new position in Pfizer Inc. (NYSE:PFE) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 7,325 shares of the biopharmaceutical company’s stock, valued at approximately $203,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC increased its stake in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares in the last quarter. Creekmur Asset Management LLC purchased a new position in Pfizer in the 4th quarter worth about $32,000. Tennessee Valley Asset Management Partners purchased a new position in Pfizer in the 4th quarter worth about $36,000. Finally, DiNuzzo Private Wealth Inc. purchased a new position in Pfizer in the 4th quarter worth about $37,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Morgan Stanley lifted their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Ten investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $35.86.

Pfizer Stock Up 0.7 %

Shares of Pfizer stock traded up $0.20 during trading on Friday, hitting $28.00. 6,199,524 shares of the stock traded hands, compared to its average volume of 40,691,266. The company has a fifty day moving average price of $27.81 and a two-hundred day moving average price of $27.69. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The stock has a market cap of $158.66 billion, a P/E ratio of -467.09, a PEG ratio of 1.08 and a beta of 0.70.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same period in the previous year, the company earned $1.23 EPS. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. Equities research analysts predict that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 6.00%. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.